Hypernatremia predicts poor survival in patients with terminal cancer: a retrospective cohort study

Minseok Seo  
Catholic University of Korea Incheon Saint Mary's Hospital

In Cheol Hwang  
Gachon University - Medical Campus  https://orcid.org/0000-0003-4677-5525

Jaehun Jung  
Gachon University Gil Medical Center

Hwanhee Lee  
Gachon University Gil Medical Center

Jae Hee Choi  
Gachon University Gil Medical Center

Jae-Yong Shim  
Yonsei University College of Medicine

Research article

Keywords: electrolyte imbalance, hypernatremia, prognosis, terminal cancer

Posted Date: December 24th, 2019

DOI: https://doi.org/10.21203/rs.2.19525/v1

License:  This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published on July 1st, 2020. See the published version at https://doi.org/10.1186/s12904-020-00607-z.
Abstract

**Background:** Although palliative care providers, patients, and their families rely heavily on accurate prognostication, the prognostic value of electrolyte imbalance has received little attention.

**Methods:** As a retrospective review, we screened inpatients with terminal cancer admitted between January 2017 and May 2019 to one hospice-palliative care unit. Clinical characteristics and laboratory results were obtained from medical records for multivariable Cox regression analysis of independent prognostic factors.

**Results:** Of the 487 patients who qualified, 15 (3%) were hypernatremic upon admission. Median survival time was 26 days. Parameters associated with shortened survival included male sex, advanced age (> 70 years), lung cancer, poor performance status, elevated inflammatory markers, azotemia, impaired liver function, and hypernatremia. In a multivariable Cox proportional hazards model, male sex (hazard ratio [HR]=1.53, 95% confidence interval [CI]: 1.15–2.04), poor performance status (HR=1.45, 95% CI: 1.09–1.94), leukocytosis (HR=1.98, 95% CI: 1.47–2.66), hypoalbuminemia (HR=2.06, 95% CI: 1.49–2.73) and hypernatremia (HR=1.55, 95% CI: 1.18–2.03) emerged as significant predictors of poor prognosis.

**Conclusion:** Hypernatremia may be a useful gauge of prognosis in patients with terminal cancer. Further corroborative studies of large scale and prospective design are needed.

**Background**

Accurately predicting the prognosis of patients with terminal cancer is essential, because it aids in clinical decisions and management plans of palliative care workers. Over the past few decades, a number of studies have been conducted in this setting to identify patient-related prognostic factors of potential use, such as performance status, anorexia-cachexia, delirium, and dyspnea [1]; and various laboratory abnormalities have similarly been identified. Serum markers of systemic inflammation (i.e., leukocytosis, lymphopenia, C-reactive protein (CRP) elevation, and inflammatory cytokines) are well-known indices of poor survival [2]. Biomarkers of hepatic dysfunction (elevated lactate dehydrogenase [LDH], prolonged international normalized ratio [INR], hypoalbuminemia) and renal impairment (serum urea, creatinine, and uric acid elevations) have been implicated as well [2, 3].

Electrolyte abnormalities are common among the terminal cancer patients and represent yet another significant means of predicting survival [4]. In an earlier study, 79% of such patients showed at least one electrolyte abnormality upon referral for palliative care [5]. Hyponatremia is the most frequent electrolyte disorder of patients with terminal cancer, having dire consequences [6]. In fact, its early detection and proper correction may actually prolong median survival time [7]. Although hypememtremia is otherwise a rarity in these patients, offering little opportunity for study, there is evidence to suggest that the prognostic ramifications again are negative [8, 9]. Potassium imbalance is also a highly prevalent electrolyte disorder. Especially in cancer patients, hypokalemia often presents in conjunction with hyponatremia and hypomagnesemia [4]. According to some, hyperkalemia is a prognostically
unfavorable determinant, but this view remains controversial [10, 11]. Research on the prognostic utility of other electrolyte disorders including hypercalcemia and hypermagnesemia, has likewise proved inconclusive [5, 12].

The present study was undertaken to assess the prevalence of electrolyte imbalance in terminally ill cancer patients, investigating the potential prognostic significance.

**Methods**

As a retrospective review, we examined medical records of 515 patients admitted to the palliative care unit of Incheon regional cancer center between January 2017 and May 2019. All participants were terminally ill with cancer and were not expected to survive beyond 6 months. Ultimately, 10 patients who lacked serum electrolyte data and 18 patients transferred from other medical institutions were excluded, leaving 487 patients eligible for final analysis. The institutional review board of Gachon University Gil Medical Center approved this study (GCIRB2019-149), waiving the need for informed patient consent as designed.

Electronic medical records provided the following patient data: age, sex, primary cancer site, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), evidence of active infection, survival times, and laboratory diagnostic results. ECOG-PS is a scale (0–4) used to assess physical ability. On day of admission, an experienced member of the palliative care team, including physicians and registered nurses, scored each patient functionally. Survival time was defined as the period from admission-day blood testing (electrolytes included) to day of death. Laboratory testing on day of admission included total white blood cell (WBC) count with differential, hemoglobin, platelet count, serum creatinine, serum albumin, total bilirubin, international normalized ratio (INR), CRP, serum sodium, and potassium.

*Statistical analysis*

Descriptive data were expressed as medians and numbers of subjects. Kaplan-Meier method and log-rank test were invoked to measure differences in survival times across all patient characteristics, using Cox proportional hazards models to identify independent predictors of survival in univariable and multivariable analyses. Variables showing significance (\( p < 0.05 \)) in univariable analysis served for final multivariable analysis. A two-tailed \( p < 0.05 \) was deemed significant. All computations were driven by standard software (Stata SE v9.2; StataCorp, College Station, TX, USA).

**Results**

A total of 487 patients (men: 268, 55%; women: 219, 45%) with terminal cancer qualified for study participation. Baseline clinical characteristics of the study population are shown in Table 1. Median age was 70 years. The most common type of malignancy was cancer of the gastrointestinal tract (127 patients, 26.1%), followed by hepatopancreatobiliary cancer (118 patients, 24.2%). ECOG-PS scores 3 and 4 were recorded in 38.8% and 37.6% of patients, respectively. Median values of abnormal laboratory
parameters were as follows: hemoglobin 10.1 g/dL, CRP 5.2 mg/dL, and sodium 134 mEq/L. The median survival time overall was 26 days.

Survival time is shown according to clinical and laboratory characteristics in Table 2. Advanced age (>70 years), male sex, lung cancer, poor performance status, leukocytosis, neutrophilia, lymphopenia, thrombocytopenia, azotemia, hypoalbuminemia, hyperbilirubinemia, prolonged prothrombin time (PT)-INR, elevated CRP, and hypernatremia were factors associated with significantly shorter median survival time.

Kaplan-Meier survival curves plotted by serum sodium level are depicted in Figure 1. In patients with hypernatremia (vs. eunatremia or hyponatremia), survival was significantly shorter (p<0.001), whereas survival in eunatremic and hyponatremic patients appeared similar.

Various parameters, including male sex (HR=1.53; p=0.004), poor ECOG-PS (HR=1.45, p=0.011), leukocytosis (HR=1.98, p<0.001), hypoalbuminemia (HR=2.06, p<0.001), and hypernatremia (HR=1.55, p=0.002), were identified by Cox proportional hazards analysis as independent prognostic factors significantly associated with survival.

**Discussion**

Findings of the present study indicate that in terminally ill cancer patients with hypernatremia (vs. eunatremia or hyponatremia), the prognosis is demonstrably poor. These results are aligned with outcomes of previous studies, offering added support. Based on a group of 259 cancer patients referred for palliative care, Alsirafy et al. encountered shorter median survival (8 days) and higher mortality (68%) in those with hypernatremia than in hyponatremic or eunatremic counterparts [9]. However, multivariable analysis of well-known prognostic factors in terminal cancer patients was not done. Our data indicate that the association between hypernatremia and poor survival remains robust after controlling for other predictors of survival.

Salahudeen et al. have also reported poor clinical outcomes involving higher mortality, longer hospitalization, and greater hospital expense in patients with hypernatremia [8]. There were some differences from our cohort of terminal patients whose life expectancies were roughly 6 months. They examined subjects admitted to a comprehensive cancer center with any stage of disease; and their focus was on iatrogenic hypernatremia, because baseline hypernatremia contributed so few patients. In our investigation, laboratory testing took place on day of admission, aimed at existing rather than acquired hypernatremia. Hence, this is perhaps the first effort to explore the prognostic utility of spontaneous hypernatremia in terminally ill cancer patients.

The prevalence of hypernatremia in patients with terminal cancer is unclear. Salahudeen and colleagues found that hypernatremia in cancer patients increased from 0.2% on admission to 2.6% during the course of hospitalization [8]. Another study has also indicated that 8.5% of adult cancer patients referred for
palliative care are hypernatremic [9]. Similar to prior studies, we recorded a 3% prevalence of hypernatremia.

Little is known of the specific mechanism by which hypernatremia worsens survival, but there is at least one plausible explanation. Hypernatremia is generally induced by the loss of electrolyte-free water. Physiologic feedback mechanisms, such as thirst and antidiuretic hormone (ADH) release, are then promptly activated to increase water intake and minimizing additional free water loss. In a healthy population, elevated serum sodium levels return to normal range accordingly [11]. However, feedback dysfunction in patients with terminal cancer may impede or prevent normalization of serum sodium concentrations, and many patients with terminal cancer are faced with non-replenishment of water lost through excessive sweating, vomiting, diarrhea, and nasogastric drainage [13]. Impaired response to thirst due to diminished mental faculties or poor oral intake and subsequent dehydration may induce hypernatremia in such patients outside hospital environments. Still, there is virtually no research on hypernatremia in cancer patients. Retrospective studies of older adult patients and critically ill patients admitted to intensive care units would be helpful to understand this problem in the context of terminal cancer [14, 15]. Mental debilitation and poor oral intake create rapid declines in their general conditions [16]. Although causality between hypernatremia and deteriorating general conditions remain in question, hypernatremic patients are extremely ill and less inclined to survive.

Certain prognostic factors, namely poor functional status, leukocytosis, and hypoalbuminemia, are well documented in past reports, but the data on effects of hyponatremia have been inconsistent. Several earlier endeavors have shown the negative prognostic aspect of hyponatremia in a variety of cancers [17, 18]. Yoon et al. have also demonstrated a relation between hyponatremia and shorter survival time in terminally ill cancer patients [19]. However, another study has failed to support this relation in Korean patients with terminal cancer entering a hospice unit, although hampered by a relatively short median survival time (9.5 days) [20]. To our knowledge, the present analysis offers the most fully controlled results in a comparable setting, adjusted for potential confounders. Also, our subjects survived longer than those in previous studies. Even so, we did not find hyponatremia predictive of poor survival under these conditions. Further prospective studies to explore the prognostic significance of hyponatremia are nevertheless warranted.

At present, evidence of the prognostic value of potassium disorders is sparse. Cui et al. have observed an association between serum potassium level and survival time, but significance was not reached in multivariable analysis [21]. In our study, hyperkalemia similarly did not emerge from multivariable analysis as a significant predictor of poor prognosis. One retrospective study conducted in Taiwan cites a serum potassium level > 5 mg/dL as an objective index of short-term survival (7 days) in patients with advanced cancer [10]. Still other researchers have found no prognostic significance attached to potassium imbalance [2, 20].

There are acknowledged limitations to interpreting the results of our study. First, the cohort is representative of a single center only, and the number of hypernatremic patients was small. Given the
prevalence of hypernatremia in terminal cancer patients, large-scale multicenter investigations would be helpful to determine the actual prognostic import of hypernatremia under such circumstances. Another drawback is the lack of sequential or interventional data on serum sodium levels. A previous study report does indicate that hyponatremia normalization is prognostically beneficial in patients with advanced non-small cell lung cancers [22]. One may thus infer that without normalization, patients with persistent hypernatremia will fare worse.

Conclusion

We have shown that hypernatremia on admission for palliative care of terminal cancer is predictive of shorter patient survival. Despite its low prevalence (3%), greater clinical attention to the prognostic utility of hypernatremia is needed.

Declarations

- Ethics approval and consent to participate: The institutional review board of Gachon University Gil Medical Center approved this study (GCIRB2019-149), waiving the need for informed patient consent as designed.

Consent for publication: Not applicable.

- Availability of data and materials: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

- Competing interests: The authors declare that they have no competing interests.

- Funding: This work was supported by the Gachon University Gil Medical Center (Grant number: FRD2019-11)

- Authors’ contributions: All authors have participated sufficiently in this work to take public responsibility for appropriate portions of the content and have read and approved the final manuscript. Specific author contributions were: MSS: analysis of data, interpretation, drafting the manuscript, and final revision. ICH: study design, analysis of data, interpretation, and critical revision of the manuscript. JHJ: study conception, design, analysis of data, and revision the statistical session. HHL: study design, acquisition of data, and analysis of data. JHC: study conception, acquisition, interpretation, and drafting sections of the manuscript. JYS: interpretation, critical revision the discussion session.

- Author details:

  1Department of Family Medicine, Incheon St. Mary’s Hospital, Seoul, Republic of Korea

; Min-Seok Seo
Yonsei University Graduate School of Medicine, Seoul, Republic of Korea

; Min-Seok Seo, Jae-Yong Shim

Department of Family Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea

; In Cheol Hwang, Hwanhee Lee, Jae Hee Choi

Artificial Intelligence and Bigdata Convergence Center, Gachon University College of Medicine, Incheon, Republic of Korea

; Jaehun Jung

- Acknowledgements: Not applicable

### Abbreviations

CRP: C- Reactive Protein

LDH: Lactate DeHydrogenase

INR: International Normalized Ratio

ECOG-PS: Eastern Cooperative Oncology Group Performance Status

WBC: White Blood Cell

ADH: AntiDiuretic Hormone

### References

1. Hui D. Prognostication of Survival in Patients With Advanced Cancer: Predicting the Unpredictable? *Cancer Control*. 2015;22:489-497.

2. Reid VL, McDonald R, Nwosu AC, Mason SR, Probert C, Ellershaw JE, et al. A systematically structured review of biomarkers of dying in cancer patients in the last months of life; An exploration of the biology of dying. *PLoS One*. 2017; 12:e0175123.

3. Kawai N, Yuasa N. Laboratory prognostic score for predicting 30-day mortality in terminally ill cancer patients. *Nagoya J Med Sci*. 2018;80:571-582.

4. Rosner MH, Dalkin AC. Electrolyte disorders associated with cancer. *Adv Chronic Kidney Dis*. 2014;21:7-17.

5. Alsirafy SA, Al-Shahri MZ, Hassan A, Hidayetullah M, Ghanem H. Pattern of electrolyte abnormalities among cancer patients referred to palliative care: A review of 750 patients. *Prog Palliat Care*. 
6. Berardi R, Rinaldi S, Caramanti M, Grohè C, Santoni M, Morgese F, et al. Hyponatremia in cancer patients: Time for a new approach. Crit Rev Oncol Hematol. 2016;102:15-25.

7. Peteriet C, Zaba O, Teber I, Grohe C. Is hyponatremia a prognostic marker of survival for lung cancer?. Pneumologie. 2011;65:565-571.

8. Salahudeen AK, Doshi SM, Shah P. The frequency, cost, and clinical outcomes of hyponatremia in patients hospitalized to a comprehensive cancer center. Support Care Cancer. 2013;21:1871-1878.

9. Alsirafy SA, Sroor MY, Al-Shahri MZ. Predictive impact of electrolyte abnormalities on the admission outcome and survival of palliative care cancer referrals. J Palliat Med. 2009;12:177-180.

10. Chen YT, Ho CT, Hsu HS, Huang PT, Lin CY, Liu CS, et al. Objective palliative prognostic score among patients with advanced cancer. J Pain Symptom Manage. 2015;49:690-696.

11. Muhsin SA, Mount DB. Diagnosis and treatment of hyponatremia. Best Pract Res Clin Endocrinol Metab. 2016;30:189-203.

12. Feliu J, Jiménez-Gordo AM, Madero R, Rodríguez-Aizcorbe JR, Espinosa E, Castro J, et al. Development and validation of a prognostic nomogram for terminally ill cancer patients. J Natl Cancer Inst. 2011;103:1613-1620.

13. Tsai JS, Wu CH, Chiu TY, Hu WY, Chen CY. Symptom patterns of advanced cancer patients in a palliative care unit. Palliat Med. 2006;20:617-622.

14. Phillips PA, Bretherton M, Johnston CI, Gray L. Reduced osmotic thirst in healthy elderly men. Am J Physiol. 1991;261:R166-171.

15. Lindner G, Funk GC. Hyponatremia in critically ill patients. J Crit Care. 2013;28:216 e211-220.

16. Stone PC, Lund S. Predicting prognosis in patients with advanced cancer. Ann Oncol. 2007;18:971-976.

17. Yang Y, Sun N, Sun P, Zhang L. Clinical Characteristics and Prognosis of Elderly Small Cell Lung Cancer Patients Complicated with Hyponatremia: A Retrospective Analysis. Anticancer Res. 2017;37:4681-4686.

18. Penttila P, Bono P, Peltola K, Donskov F. Hyponatremia associates with poor outcome in metastatic renal cell carcinoma patients treated with everolimus: prognostic impact. Acta Oncol. 2018;57:1580-1585.

19. Yoon J, Ahn SH, Lee YJ, Kim CM. Hyponatremia as an independent prognostic factor in patients with terminal cancer. Support Care Cancer. 2015;23:1735-1740.

20. Lee GJ, Ahn HS, Go SE, Kim JH, Seo MW, Kang SH, et al. Patient’s Factors at Entering Hospice Affecting Length of Survival in a Hospice Center. Cancer Res Treat. 2015;47:1-8.

21. Cui J, Zhou L, Wee B, Shen F, Ma X, Zhao J. Predicting survival time in noncurative patients with advanced cancer: a prospective study in China. J Palliat Med. 2014;17:545-552.

22. Berardi R, Santoni M, Newsom-Davis T, Caramanti M, Rinaldi S, Tiberi M, et al. Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung
Tables

Table 1. Characteristics of study participants (N=487)

| Characteristic                        | Median (IQR) or n (%) | Reference range |
|---------------------------------------|-----------------------|-----------------|
| Age, yrs                              | 70 (59–79)            |
| Female sex                            | 219 (45.0)            |
| Cancer site                           |                       |
| Gastrointestinal tract                | 127 (26.1)            |
| Hepatobiliary/pancreatic              | 118 (24.2)            |
| Lung                                  | 108 (22.2)            |
| Urogenital tract                      | 57 (11.7)             |
| Others                                | 77 (15.8)             |
| ECOG-PS                               |                       |
| ≤ 2                                   | 115 (23.6)            |
| 3                                     | 189 (38.8)            |
| 4                                     | 183 (37.6)            |
| Active infection                      | 164 (33.7)            |
| Laboratory parameter                  |                       |
| White blood cells, $10^3$/mm$^3$      | 9.1 (6.3–12.7)        | 3.8–10          |
| Neutrophils, %                        | 78.9 (72.0–85.7)      | 50–75           |
| Lymphocytes, %                        | 11.2 (6.8–17.4)       | 20–44           |
| Hemoglobin, g/dL                      | 10.1 (8.8–11.7)       | 13–17           |
| Platelets, $10^3$/mm$^3$               | 227 (154–323)         | 150–400         |
| Creatinine, mg/dL                     | 0.8 (0.5–1.2)         | 0.5–1.2         |
| Albumin, g/dL                         | 3.2 (2.8–3.7)         | 3.5–5.2         |
| Total bilirubin, mg/dL                | 0.7 (0.5–1.4)         | 0.2–1.2         |
| PT/INR                                | 1.2 (1.1–1.3)         | 0.8–1.2         |
| C-reactive protein, mg/dL             | 5.2 (2.3–12.9)        | 0–0.5           |
| Sodium, mEq/L                         | 134 (130–137)         | 135–145         |
| Potassium, mEq/L                      | 4.2 (3.8–4.6)         | 3.5–5.5         |
| Censored                              | 19 (3.9)              |
| Survival time, days                   | 26 (14–45)            |

ECOG-PS, Eastern Cooperative Oncology Group performance status; PT/INR, prothrombin time/international normalized ratio; IQR, interquartile range
### Table 2. Survival time in relation to patient characteristics

|                          | N  | Median survival, days (95% CI) | \( p^b \) |
|--------------------------|----|-------------------------------|----------|
| **Age, years**           |    |                               |          |
| <70                      | 232| 29 (13–52)                    | 0.003    |
| ≥70                      | 255| 24 (14–40)                    |          |
| **Sex**                  |    |                               |          |
| Female                   | 219| 29 (13–48)                    | 0.035    |
| Male                     | 268| 24 (14–40)                    |          |
| **Cancer site**          |    |                               |          |
| Gastrointestinal tract   | 127| 29 (14–47)                    | 0.012    |
| Hepatobiliary/pancreatic | 118| 24 (13–33)                    |          |
| Lung                     | 108| 22 (12–41)                    |          |
| Urogenital tract         | 57 | 27 (13–55)                    |          |
| Others                   | 77 | 35 (19–47)                    |          |
| **ECOG-PS**              |    |                               |          |
| ≤2                       | 115| 30 (18–50)                    | 0.012    |
| 3                        | 189| 27 (14–48)                    |          |
| 4                        | 183| 23 (11–40)                    |          |
| **Active infection**     |    |                               |          |
| No                       | 322| 27 (12–46)                    | 0.558    |
| Yes                      | 164| 25 (14–38)                    |          |
| **Leukocytosis**         |    |                               |          |
| No                       | 279| 31 (15–52)                    | <0.001   |
| Yes                      | 208| 22 (11–34)                    |          |
| **Neutrophilia**         |    |                               |          |
| No                       | 173| 31 (18–55)                    | <0.001   |
| Yes                      | 314| 24 (12–39)                    |          |
| **Lymphopenia**          |    |                               |          |
| No                       | 90 | 36 (19–60)                    | <0.001   |
| Yes                      | 397| 25 (13–41)                    |          |
| **Anemia**               |    |                               |          |
| No                       | 56 | 25 (13–45)                    | 0.707    |
| Yes                      | 431| 26 (14–45)                    |          |
| **Thrombocytopenia**     |    |                               |          |
| No                       | 371| 28 (14–47)                    | 0.020    |
| Yes                      | 116| 20 (11–36)                    |          |
| **Azotemia**             |    |                               |          |
| No                       | 367| 28 (14–46)                    | 0.011    |
| Yes                      | 120| 20 (12–38)                    |          |
| **Hypoalbuminemia**      |    |                               |          |
| No                       | 176| 35 (20–60)                    | <0.001   |
| Yes                      | 311| 20 (11–37)                    |          |
| **Hyperbilirubinemia**   |    |                               |          |
| No                       | 341| 29 (15–48)                    | <0.001   |
| Yes                      | 145| 19 (10–32)                    |          |
| **PT/INR prolongation**  |    |                               |          |
| No                       | 259| 29 (16–51)                    | <0.001   |
| Yes                      | 200| 20 (10–34)                    |          |
| **C-reactive protein**   |    |                               |          |
| Low                      | 239| 29 (14–52)                    | 0.007    |
| High                     | 233| 22 (12–38)                    |          |
| **Sodium level**         |    |                               |          |
| Within normal range      | 219| 28 (14–49)                    | <0.001   |
| Hyponatremia             | 253| 25 (13–43)                    |          |
| Hypernatremia            | 15 | 6 (3–28)                      |          |
| **Potassium level**      |    |                               |          |
| Within normal range      | 394| 27 (14–46)                    | 0.118    |
| Hypokalemia              | 65 | 26 (13–43)                    |          |
| Hyperkalemia             | 28 | 19 (10–27)                    |          |

*aMedian value applied
bLog-rank test
ECOG-PS, Eastern Cooperative Oncology Group performance status; PT/INR, prothrombin time/international normalized ratio; CI, confidence interval

### Table 3. Independent prognostic indices of survival (Cox proportional hazards model)
| Variable                                      | Univariable analysis | Multivariable analysis<sup>a</sup> |
|----------------------------------------------|----------------------|-----------------------------------|
|                                              | HR (95% CI)           | P-value                           |
|                                              |                      |                                   |
| Advanced age (>70 years)                     | 1.31 (1.09–1.58)     | 0.004                             |
| Male sex                                     | 1.21 (1.01–1.46)     | 0.038                             |
| Poor functional score (ECOG=4)               | 1.30 (1.08–1.57)     | 0.005                             |
| Lung cancer                                  | 1.20 (0.96–1.50)     | 0.108                             |
| Active infection                              | 1.06 (0.87–1.28)     | 0.564                             |
| Leukocytosis                                 | 1.56 (1.29–1.87)     | <0.001                            |
| Neutrophilia                                 | 1.45 (1.19–1.75)     | <0.001                            |
| Lymphopenia                                  | 1.53 (1.20–1.94)     | 0.001                             |
| Anemia                                       | 0.95 (0.71–1.26)     | 0.711                             |
| Thrombocytopenia                             | 1.28 (1.04–1.59)     | 0.022                             |
| Azotemia                                     | 1.30 (1.06–1.61)     | 0.013                             |
| Hypoalbuminemia                              | 1.88 (1.54–2.28)     | <0.001                            |
| Hyperbilirubinemia                           | 1.47 (1.21–1.80)     | <0.001                            |
| PT/INR prolongation                          | 1.46 (1.21–1.77)     | <0.001                            |
| CRP elevation                                | 1.28 (1.07–1.54)     | 0.008                             |
| Hypokalemia                                  | 1.01 (0.77–1.32)     | 0.958                             |
| Hyperkalemia                                 | 1.22 (1.01–1.48)     | 0.044                             |
| Hyponatremia                                 | 1.24 (1.03–1.49)     | 0.025                             |
| Hypernatremia                                | 1.59 (1.22–2.07)     | 0.001                             |
|                                              | 1.55 (1.18–2.03)     | 0.002                             |

<sup>a</sup>Based on variables of significance (p<0.05) in univariable analysis

PT/INR, prothrombin time/international normalized ratio; CRP, C-reactive protein

Figures
Figure 1

Kaplan-Meier survival curves of terminal cancer patients plotted by sodium level (note significantly shorter survival in patients with hypernatremia).